ERBB2阳性转移性结直肠癌的诊断与治疗:一篇综述
ERBB2扩增见于约3%的转移性结直肠癌患者及5%的KRAS和NRAS野生型肿瘤患者,目前尚无获批疗法但NCCN指南已推荐ERBB2靶向治疗。本综述汇总免疫组化、荧光原位杂交、二代测序和液体活检等检测方法及单克隆抗体、抗体药物偶联物、酪氨酸激酶抑制剂等靶向策略的随机临床试验证据,认为ERBB2是有前景的靶点。
要点
- ERBB2扩增见于约3%的转移性结直肠癌患者及5%的KRAS和NRAS野生型肿瘤患者。
- ERBB2扩增的结直肠肿瘤更常起源于左侧结肠,与抗EGFR治疗的原发性和获得性耐药相关,中枢神经系统转移发生率增加。
- 目前尚无获批用于ERBB2阳性转移性结直肠癌的疗法,但NCCN指南已推荐ERBB2靶向治疗。
核心结论
- 本综述结果提示ERBB2受体是转移性结直肠癌患者有前景的靶点,但迄今尚无疗法获批用于该患者人群。
- 作者认为必须继续努力解决这一未满足的需求,使ERBB2阳性转移性结直肠癌患者在对标准治疗耐药后仍有治疗选择。
研究设计与样本
- 本综述汇总了采用免疫组化、荧光原位杂交、二代测序和液体活检技术评估ERBB2靶向治疗在ERBB2阳性转移性结直肠癌患者中疗效的若干随机临床试验。
主要发现
- ERBB2扩增导致ERBB2酪氨酸激酶受体过表达,引起异常信号传导及细胞迁移、生长、黏附和分化。
- ERBB2扩增的结直肠肿瘤更常起源于左侧结肠,与抗表皮生长因子受体治疗的原发性和获得性耐药相关,中枢神经系统转移发生率增加。
- 综述涉及的ERBB2靶向治疗包括单克隆抗体、抗体药物偶联物和酪氨酸激酶抑制剂,其中许多在治疗ERBB2阳性转移性结直肠癌时具有有利的疗效和安全性特征。
关键数值与推荐
- ERBB2扩增见于约3%的转移性结直肠癌患者及5%的KRAS和NRAS野生型肿瘤患者。
- 美国国家综合癌症网络(NCCN)指南推荐对ERBB2阳性转移性结直肠癌患者使用ERBB2靶向治疗。
临床怎么用
- 美国国家综合癌症网络(NCCN)指南推荐对ERBB2阳性转移性结直肠癌患者使用ERBB2靶向治疗。
- 原文未据此给出其他临床推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Amplification of ERBB2 (formerly referred to as HER2) is present in nearly 3% of patients with metastatic colorectal cancer overall and 5% of patients with KRAS and NRAS wild-type tumors. Despite the availability of several ERBB2-targeted therapeutic options for patients with ERBB2-positive breast and gastric/gastroesophageal tumors, to date, there are currently no approved therapies for patients with ERBB2-positive metastatic colorectal cancer, although ERBB2-targeted therapies are recommended in National Comprehensive Cancer Network guidelines. Recent evidence indicates that anti-ERBB2 therapeutic strategies are active in patients with ERBB2-positive metastatic colorectal cancer and could potentially represent a new standard-of-care. OBSERVATIONS: The protein ERBB2 is a member of a family of epidermal growth factor receptors that also includes epidermal growth factor receptor (ERBB1), ERBB3, and ERBB4. Amplification of ERBB2 leads to overexpression of the ERBB2 tyrosine kinase receptor, resulting in aberrant signaling and cell migration, growth, adhesion, and differentiation. Colorectal tumors that harbor ERBB2 amplification are more likely to originate on the left side of the colon, are associated with primary and acquired resistance to anti-epidermal growth factor receptor therapies, and have increased incidence of central nervous system metastases. Using immunohistochemistry, fluorescence in situ hybridization, next-generation sequencing, and liquid biopsy techniques, several randomized clinical trials have evaluated the efficacy of ERBB2-targeted therapies in patients with ERBB2-positive metastatic colorectal cancer. These therapies include monoclonal antibodies, antibody-drug conjugates, and tyrosine kinase inhibitors, many of which were associated with favorable efficacy and safety profiles when treating patients with ERBB2-positive metastatic colorectal cancer. CONCLUSIONS AND RELEVANCE: The results of this review suggest the ERBB2 receptor is a promising target for patients with metastatic colorectal cancer; however, to date, no therapies are approved for use in this patient population. Therefore, it is imperative to continue to work to address this unmet need so that patients with ERBB2-positive metastatic colorectal cancer have therapeutic options should they become refractory to treatment with standard therapies.
引用
- Strickler JH, Yoshino T, Graham RP, et al. Diagnosis and Treatment of ERBB2-Positive Metastatic Colorectal Cancer: A Review. JAMA Oncol. 2022. PMID: 35238866. doi:10.1001/jamaoncol.2021.8196
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。